Financial Astrology of Amgen Inc.

FINANCIAL ASTROLOGY

First Trade Date for Amgen Inc.

Company Name	First Trade Date (yyyy-mm-dd)
Amgen Inc.	1983-06-17

Company Name	Symbol
Amgen Inc.	AMGN
History and Business of Company (this information may include date of incorporation)
Amgen Inc. (including its subsidiaries, "Amgen" or the "Company") is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology. In July 2002, Amgen completed its acquisition of Immunex Corporation ("Immunex"). Immunex was a leading biotechnology company dedicated to developing immune system science to protect human health. The Company markets human therapeutic products including, EPOGEN(r) (Epoetin alfa), Aranesp(r) (darbepoetin alfa), NEUPOGEN(r) (Filgrastim), Neulasta(tm) (pegfilgrastim), and Kineret(r) (anakinra). Amgen acquired the rights to ENBREL(r) (etanercept) as a result of the Immunex acquisition. ENBREL(r) is marketed with Wyeth under a co-promotion agreement. EPOGEN(r) stimulates the production of red blood cells and is marketed in the United States for the treatment of anemia associated with chronic renal failure in patients on dialysis. Aranesp(r) stimulates the production of red blood cells and is marketed in the United States, most countries in Europe, Australia, and New Zealand for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis. Aranesp(r) is also marketed in the United States for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies. Aranesp(r) is approved in Europe for the treatment of anemia in adult cancer patients with solid tumors receiving chemotherapy, and has been launched in several countries in Europe for this indication. NEUPOGEN(r) selectively stimulates the production of neutrophils, one type of white blood cell. The Company markets NEUPOGEN(r) in the United States, certain countries in Europe, Canada, and Australia for use in decreasing the incidence of infection in patients undergoing myelosuppressive chemotherapy. In addition, NEUPOGEN(r) is marketed in most of these countries for use in increasing neutrophil counts in various other treatment modalities. The Company began marketing Neulasta(tm) in the United States in April 2002 to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. In August 2002, the European Commission approved Neulasta(tm) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients with cytotoxic chemotherapy for malignancy. In January 2003, the Company commenced launching Neulasta(tm) in Europe on a country-by-country basis as reimbursement has been established. ENBREL(r) blocks the biologic activity of tumor necrosis factor ("TNF") by competitively inhibiting TNF, a substance induced in response to inflammatory and immunological responses. ENBREL(r) is marketed in the United States and Canada for the reduction of the signs and symptoms in patients with moderately to severely active rheumatoid arthritis. Kineret(r) blocks the biologic activity of interleukin-1 ("IL-1"), a substance that mediates inflammatory and immunological responses. Kineret(r) is marketed in the United States for the reduction of the signs and symptoms of moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs. Kineret(r) is also approved for use in Europe and Canada. In addition, Amgen has entered into licensing and/or co-promotion agreements to market certain of its products including Aranesp(r), NEUPOGEN(r), and Neulasta(tm) in certain geographic areas outside of the United States. The Company focuses its research and development efforts on human therapeutics delivered in the form of proteins, monoclonal antibodies, and small molecules in the areas of nephrology, oncology, inflammation, neurology, and metabolic disorders. The Company has research facilities in the United States, and has clinical development staff in the United States, Europe, Canada, Australia, and Japan. In addition to internal research and development efforts, the Company has acquired certain product and technology rights and has established research and development collaborations. The Company manufactures EPOGEN(r), Aranesp(r), NEUPOGEN(r), Neulasta(tm), ENBREL(r), and Kineret(r). Amgen operates commercial manufacturing facilities located in the United States, Puerto Rico, and a packaging and distribution center in The Netherlands. Additional supply of ENBREL(r) is produced by contract manufacturers. A sales and marketing force is maintained in the United States, Europe, Canada, Australia, and New Zealand. The Company was incorporated in California in 1980 and was merged into a Delaware corporation in 1987. Amgen's principal executive offices are located at One Amgen Center Drive, Thousand Oaks, California 91320-1799.

IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.